Adicet bio to present at upcoming investor conferences

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in may and june. details of the events are as follows: h.c. wainwright global investment conference, may 23-26, 2022 an on-demand presentation will be available
ACET Ratings Summary
ACET Quant Ranking